Arcturus Therapeutics Holdings Inc. (ARCT)

27,56 +0,24 (+0,88%) Alla chiusura: 04:00PM EDT

Arcturus Therapeutics Holdings Inc.

10628 Science Center Drive
Suite 250
San Diego, CA 92121
United States
858 900 2660
https://arcturusrx.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 180

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Joseph E. Payne M.Sc.	Founder, President, CEO & Director	906,5k	N/D	1972
Dr. Padmanabh Chivukula Ph.D.	Founder, Chief Scientific Officer, COO & Secretary	687,5k	N/D	1979
Mr. Andrew H. Sassine MBA	CFO & Director	687,5k	N/D	1964
Mr. Lance Kurata	Chief Legal Officer	600k	N/D	N/D
Ms. Neda Safarzadeh	Vice President and Head of IR/PR & Marketing	N/D	N/D	N/D
Ms. Natash O. Bowman	Chief Human Resources Officer	N/D	N/D	N/D
Mr. Kevin T. Skol	Chief Business Officer	N/D	N/D	N/D
Dr. Juergen Froehlich FCPh, M.D., MBA	Chief Medical Officer	N/D	N/D	1956
Dr. Igor Smolenov M.D., Ph.D.	Chief Development Officer	N/D	N/D	N/D
Joseph Roberts	Controller	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Governance aziendale

L'ISS Governance QualityScore di Arcturus Therapeutics Holdings Inc. al 1 maggio 2024 è 9. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 4; diritti degli azionisti: 6; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.